Cargando…
Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects
CONTEXT: Velcalcetide, also known as AMG 416, is a novel, long-acting selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease—mineral and bone disorder. O...
Autores principales: | Martin, Kevin J., Bell, Gregory, Pickthorn, Karen, Huang, Saling, Vick, Andrew, Hodsman, Peter, Peacock, Munro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910343/ https://www.ncbi.nlm.nih.gov/pubmed/24235081 http://dx.doi.org/10.1093/ndt/gft417 |
Ejemplares similares
-
Comparison of AMG 416 and cinacalcet in rodent models of uremia
por: Walter, Sarah, et al.
Publicado: (2014) -
Pharmacokinetics, Biotransformation, and Excretion of [(14)C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis
por: Subramanian, Raju, et al.
Publicado: (2016) -
Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo Through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia
por: Mace, Maria L., et al.
Publicado: (2017) -
The R416 Cerenkov counters
por: Meyer, W T
Publicado: (1980) -
Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol
por: Cheng, Qun, et al.
Publicado: (2018)